It’s no surprise that consumers are increasingly worried about immunity.
Amidst fears of health concerns, sparked by the global COVID-19 pandemic, sales of immunity supplements have soared.
Globally, one in two consumers have purchased probiotic products in the past year*, and Fonterra is ready to expand into this market.
Fonterra has landed a probiotics supply agreement with GMP Pharmaceuticals – the largest third-party supplement manufacturer in Australasia.
Throughout the next 12 months, Fonterra will supply NZMP SureStart™ probiotics, made at Fonterra’s Microbial Fermentation Unit in Palmerston North, for all GMP’s paediatrics products for young children and pregnant women in Australia.
Fonterra Australia Director Nutritionals and Value Add Ingredients Fabrizio Jorge says the partnership is the result of a trans-Tasman collaboration across the business.
“We're supplying GMP with our great New Zealand-made probiotics, which will go into pills, liquids and sachets for paediatric and pregnancy products.
“This partnership gives us access to the paediatrics supplement market in Australia and ties in with our strategy about adding value in the paediatric space.
“We’re growing our capability in this space and building awareness of the health benefits of probiotics generally.”
Fabrizio says the supplement market is an important area of expansion for Fonterra.
“It’s a sector with good opportunity for growth, with the global probiotic market estimated to be worth between US$40-60 billion*,” says Fabrizio.
* Google Trends June 2020. Available from: https://trends.google.com
* FMCG Gurus Global Perception of Ingredients Survey Q3 2018
* Grand View Research – Probiotics Market Size, Share & Trends Analysis Report By Product (Food & Beverages, Dietary Supplements), By Ingredient (Bacteria, Yeast), By End Use, By Distribution Channel, And Segment Forecasts, 2019 – 2025. Available from: https://www.grandviewresearch.com/industry-analysis/probiotics-market